12月9日，科森科技发布关于出售全资子公司股权的公告。公告显示，公司拟向江苏耀岭科医疗科技有限公司（简称"耀岭科"） 出售全资子公司江苏科森医疗器械有限公司（简称"科森医疗"）100%股权，交易金额为9.15亿元。 据了解，本次交易旨在优化公司资产结构，契合公司战略规划与业务发展需求。科森医疗成立于2018年7月，注册资本1.18亿 元，主营微创手术器械产品加工与出口业务。受外部市场环境变迁及中美贸易摩擦持续影响，其业务发展面临挑战，且技术路 径与客户群体均与科森科技核心主业差异较大，协同效应有限。此次出售非核心业务，将助力科森科技全面聚焦主业及新兴产 业，改善公司业绩，实现可持续发展。 根据股权转让协议约定，耀岭科需在协议签署后10个工作日内支付100万美元意向金（后续全额退还）；在满足交割先决条件后 的15个工作日内支付50%首期价款，并提供银行贷款出资承诺函；在完成工商变更后的15个工作日内支付剩余50%价款。过渡期 内，科森医疗需维持正常经营，未经耀岭科书面同意，不得进行重大资本支出、资产处置、借款担保等行为。科森科技董事会 表示，FSP资信状况良好，具备足额支付能力。 交易对方耀岭科为FSP全资子公 ...

Core Viewpoint - Mindray Medical has completed a systematic restructuring in Wuhan, with Mindray becoming the controlling shareholder of Wuhan Mindray Technology after a series of capital and organizational changes, including an increase in registered capital from 300 million to 2.3 billion yuan [2][4]. Group 1: Capital Structure and Corporate Changes - The registered capital increase corresponds with the previous capital of the merged entity, forming a logical closure [4]. - The merger and change of legal representative signify a return to a "single entity" framework, enhancing governance and operational efficiency [4][20]. - The restructuring is part of a broader strategy to unify governance structures, which is common among large medical device companies [4][20]. Group 2: Overview of Wuhan Operations - The Wuhan operations are not limited to a single orthopedic consumables company; Mindray has been developing a second headquarters in Wuhan, with an investment of approximately 4.5 billion yuan [5]. - The Wuhan base encompasses a large-scale R&D and manufacturing facility, covering three main areas: minimally invasive surgery, orthopedics, and cardiovascular technologies [5][7]. Group 3: R&D and Manufacturing Capabilities - The Wuhan R&D center features extensive laboratory facilities and supports technology transfer, engineering validation, and global customer training, establishing a comprehensive capability platform [8]. - The manufacturing base in Wuhan is a key node in Mindray's global supply chain, producing orthopedic materials and minimally invasive surgical instruments [9]. Group 4: Strategic Reasons for the Merger - The merger is seen as a necessary step for Mindray to clarify its operations in Wuhan, aligning R&D, manufacturing, and business lines under a unified governance structure [10][11]. - The integration allows for better collaboration between orthopedic and minimally invasive business lines, transitioning from project-based initiatives to systematic capability development [12]. Group 5: Future Role of Wuhan Operations - Post-merger, Wuhan Mindray Technology is positioned to become a critical capability center for Mindray's surgical and orthopedic systems, aligning with the company's strategic focus on surgical platforms and orthopedic consumables [15][23]. - The integrated structure in Wuhan enables a complete "R&D-manufacturing-training" loop, which is crucial for the fast-paced development of minimally invasive and orthopedic products [17][18]. - Wuhan is expected to serve as a second growth hub for Mindray, complementing its headquarters in Shenzhen and facilitating a multi-center collaborative organizational model [19][21].

12月8日晚间，精密零部件供应商科森科技（603626）发布公告，公司拟以9.15亿元人民币的对价将其持有的科森医疗100%的股权转让给耀岭科，增值率 206.45%。这笔交易意味着科森科技将彻底退出医疗器械领域，也标志着其战略重心的一次重大调整。 值得注意的是，科森科技境外业务发展较快。2024年，公司境外营业收入达21.09亿元，同比增长26.45%。 今年11月26日，科森科技发布对外投资公告，公司拟在马来西亚投资新建生产基地，满足境外客户的订单需求。 科森科技称，本次对外转让科森医疗100%股权，主要目的为公司拟全面退出医疗业务，进一步聚焦消费电子主业，提升公司的经营水平和质量，符合公 司长远发展的战略规划。本次股权转让有利于实现资金回笼，降低公司资金压力，所获得的款项将用于补充公司流动资金，用于公司日常生产经营。 公开信息显示，科森科技成立于2010年，是专业从事精密结构件研发、制造与服务的高新技术企业，为客户提供消费电子、医疗器械、新能源汽车、电子 烟、光伏发电等终端产品所需精密金属、塑胶结构件以及部分组装服务。公司于2017年2月在上海证券交易所主板上市。 业绩方面，科森科技2025年三季报显示 ...

科森医疗成立于2018年7月，注册资本1.18亿元，主要经营微创手术器械加工与出口业务。受外部市场 环境变迁与中美贸易摩擦持续影响，其业务发展已面临挑战，且与公司核心主业协同效应有限。 据公告，本次交易完成后，科森医疗将不再纳入公司合并报表范围。经初步测算，预计将增加公司2025 年度投资收益约6亿元，有利于实现资金回笼，降低资金压力，所获款项将用于补充流动资金。此举旨 在优化公司资产结构，全面退出医疗业务，进一步聚焦消费电子主业，提升经营水平和质量。 科森科技主要以精密压铸、锻压、冲压、CNC、激光切割等制造工艺为基础，为苹果、华为、亚马 逊、谷歌等国际知名客户提供消费电子、医疗器械、汽车等终端产品所需精密结构件产品的研发、制造 及部分组装服务。 核校：孙萍 交易对方耀岭科为FSP Holdings Pte. Ltd的全资子公司，专为此次收购设立。FSP是一家位于新加坡的医 疗器械CDMO公司，由LYFE Capital控股，后者是一家全球医疗领域投资平台，管理资产超过20亿美 元。 ...

【科森科技拟9.15亿元出售科森医疗100%股权】12月8日，科森科技(603626.SH)公告透露，拟向江苏耀 岭科医疗科技有限公司出售全资子公司江苏科森医疗器械有限公司100%股权，交易金额9.15亿元。科 森医疗主营微创手术器械产品加工与出口业务，受外部市场环境和中美贸易摩擦影响，业务发展遇挑 战。此外，其技术路径和客户群体与公司核心主业差异大，协同效应有限。为优化资产配置，聚焦主业 及新兴产业，公司决定出售该股权。 本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担 和讯猎报 12.08 21:12:15 周- 科森科技:拟9.15亿出售科森医疗 100%股权 扫码查看原文 【科森科技拟9.15亿元出售科森医疗100%股权】 12月8日,科森科技(603626.SH)公告透露,拟向江 苏耀岭科医疗科技有限公司出售全资子公司江苏科 森医疗器械有限公司100%股权,交易金额9.15亿 元。科森医疗主营微创手术器械产品加工与出口业 务,受外部市场环境和中美贸易摩擦影响,业务发 展遇挑战。此外,其技术路径和客户群体与公司核 心主业差异大,协同效应有限。为优化资产配置, 聚焦主业及新兴产业,公司决定出 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 科森科技(603626.SH)公告称，公司拟向江苏耀岭科医疗科技有限公司（简称"耀岭科"）出售全资子公 司江苏科森医疗器械有限公司（简称"科森医疗"）100%的股权，交易金额为9.15亿元。科森医疗主要经 营微创手术器械产品的加工与出口业务，受外部市场环境变迁与中美贸易摩擦持续影响，其业务发展已 面临挑战。同时，科森医疗在其技术路径与客户群体均与公司核心主业存在差异，协同效应有限。为优 化整体资产配置，剥离非核心业务，全面聚焦主业及新兴产业，公司决定出售所持有的科森医疗100% 的股权。 ...

Group 1 - The core investment of 4.5 billion yuan in the establishment of Mindray Medical's second global headquarters in Wuhan aims to accelerate the development of a biomedicine and medical device industry cluster in the region [1][2] - The Wuhan base covers an area of 110 acres and includes a research and development base and a production base, featuring approximately 13,000 square meters of specialized laboratory space and over 90 laboratories [1] - The production base will focus on high-end manufacturing of orthopedic materials, minimally invasive surgical instruments, and biological raw materials, leveraging digital construction [1] Group 2 - Mindray Medical's senior vice president stated that the Wuhan base will serve as a "cultivation dish" for the company's second growth curve, encompassing the entire value chain from R&D to manufacturing and customer training [2] - The base plans to recruit 2,000 employees within five years, with 60% of them being R&D talents, supported by local talent policies to create a "Silicon Valley-like" ecosystem [2] - The establishment of the base is expected to attract over 100 supporting enterprises, further enhancing the high-end medical equipment industry cluster in Wuhan [2] Group 3 - Mindray Medical is recognized as China's largest and a global leader in the medical device sector, with products spanning life information and support, in vitro diagnostics, and medical imaging, distributed in over 190 countries and regions [2] - The registered capital of Mindray's wholly-owned subsidiary in Wuhan increased from 500 million yuan to 2 billion yuan in June, marking a 300% increase [2] - The president of Mindray emphasized that Wuhan is not only a crucial talent supply base but also a core component of the company's long-term strategy [2]

Group 1: Company Developments - United Imaging announced a plan to reduce holdings by up to 13,376,600 shares, corresponding to a market value of approximately 1.78 billion yuan, marking the second large-scale reduction following a cash-out of 894 million yuan in July 2024 [1][2] - The share reduction involves five employee stockholding platforms, with the shares being original stocks granted before the company's IPO, which became tradable on August 22, 2023 [2] - Despite a decline in revenue and net profit for 2024, United Imaging maintains its position as a leader in the domestic medical imaging sector, with a market share of 35% for PET-CT and over 20% for MRI equipment [3][4] Group 2: Financial Performance - United Imaging's revenue for 2024 was 10.3 billion yuan, a year-on-year decrease of 9.73%, while net profit dropped by 36.08% to 1.262 billion yuan [3] - The decline in performance is attributed to the impact of domestic equipment update policies and the lengthy market introduction period for new high-end products [3] Group 3: Competitive Landscape - In contrast to United Imaging's challenges, Mindray Medical is accelerating its global expansion, with the opening of a new base in Wuhan, representing a significant investment of 4.5 billion yuan [5][6] - Mindray has established a robust domestic network with 36 subsidiaries and over 30 branches, while also expanding its international presence with 63 overseas subsidiaries in about 40 countries [6][8] - The company is focusing on localized operations, with over 90% of its overseas team being local hires, and is customizing products to meet regional market needs [8] Group 4: Strategic Initiatives - Mindray's global strategy includes significant R&D investments, with 4.008 billion yuan allocated in 2025, accounting for 10.91% of its revenue [7] - The Wuhan base will focus on minimally invasive surgery and orthopedic fields, enhancing Mindray's production capabilities [6][7] - There are ongoing discussions about a potential second listing in Hong Kong, which could raise at least 1 billion USD to support global expansion efforts [8]